Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

288P - The role of organ-specific response to enfortumab vedotin on survival in advanced urothelial carcinoma patients: A Japanese multicenter retrospective study

Date

07 Dec 2024

Session

Poster Display session

Presenters

Nozomi Hayakawa

Citation

Annals of Oncology (2024) 35 (suppl_4): S1505-S1530. 10.1016/annonc/annonc1689

Authors

N. Hayakawa1, G. Kaneko2, D. Ikarashi3, Y. Endo4, Y. Sakura5, R. Yamashita5, W. Obara3, Y. Kondo4, E. Kikuchi1

Author affiliations

  • 1 Department Of Urology, St. Marianna University School of Medicine, 216-8511 - Kanagawa/JP
  • 2 Department Of Urology, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP
  • 3 Department Of Urology, Iwate Medical University School of Medicine, 020-8505 - Morioka/JP
  • 4 Department Of Urology, Nippon Medical School Main Hospital, 113-8603 - Tokyo/JP
  • 5 Division Of Urology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP

Resources

This content is available to ESMO members and event participants.

Abstract 288P

Background

Enfortumab vedotin (EV) monotherapy is a last-line salvage therapy for unresectable and/or metastatic urothelial carcinoma (u/mUC) in Japan. However, the impact of the response of EV to metastatic sites on survival outcomes is not fully understood.

Methods

From the time of approval to May 2024, we identified 117 u/mUC patients treated with EV at 5 institutions. The median follow-up period was 9.6 months (range: 1.0-30.0 months). We evaluated the association between metastatic sites and the treatment response to EV, as well as overall survival (OS).

Results

Overall, the response rate (complete response, CR + partial response, PR) was 49.5%. The median OS and progression-free survival were 13.9 and 6.2 months, respectively. In 56 patients with single-organ metastases, 1, 15, 8, 2, and 30 patients had liver, lung, bone, peritoneal, and lymph node (LN) metastases, respectively. The organ-specific response rate of liver, lung, bone, peritoneal, and LN metastases to EV was 35.7%, 62.2%, 18.8%, 30.8%, and 47.6%, respectively. Among them, the median OS of patients with a response to EV was not reached, which was significantly longer than their counterparts (9.2 months, p<0.001). Furthermore, in 30 patients with single-organ metastasis of LN, the median OS of patients with a response to EV was not reached, which was significantly longer than that of those without a response to EV (11.6 months, p=0.003). In 26 patients with single-organ metastasis of non-LN, all patients with a response to EV survived, but the median OS of those without a response to EV was 7.0 months (p<0.001). In 57 patients with multiple-organ metastases, 39, 11, and 9 patients had two, three, and more than three-organ metastases, respectively. Among them, the median OS of patients with a response to EV was 15.3 months, which was significantly longer than their counterparts (7.9 months, p<0.001). Furthermore, in 25 patients with multiple-organ metastases and a response to EV, there was no difference in OS between patients with a CR at least one organ and those without a CR in any organs.

Conclusions

The response to EV is associated with longer survival in u/mUC patients, irrespective of having single or multiple-organ metastases.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

N. Hayakawa: Financial Interests, Personal, Invited Speaker: Astellas Pharma Inc., Daiichi Sankyo Company Ltd, Merck & Company, Inc., Takeda Pharmaceuticals, Nippon Kayaku Co., Ltd. G. Kaneko: Financial Interests, Personal, Invited Speaker: Astellas Pharma Inc. Y. Endo: Financial Interests, Personal, Invited Speaker: Astellas Pharma Inc., Merck & Company, Inc., Nippon Kayaku Co., Ltd. W. Obara: Financial Interests, Personal and Institutional, Research Grant: Astellas Pharma Inc., AstraZeneca, Pfizer Inc., Ono Pharmaceutical, Taiho Pharmaceuticals. Y. Kondo: Financial Interests, Personal, Invited Speaker: Astellas Pharma Inc., Nippon Kayaku Co., Ltd., Bristol Meyers Squibb. E. Kikuchi: Financial Interests, Personal, Invited Speaker: MSD, Bristol, Janssen, Astellas, Merck Biopham, Nippon Kayaku, Pfizer, AstraZeneca; Financial Interests, Personal, Advisory Board: Astellas, MSD, Bristol, Janssen, Merck Biopham; Financial Interests, Institutional, Research Grant: Takeda, Nippon Kayaku, Kyorin, Taiho, Nippon Shinyaku. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.